(Total Views: 1214)
Posted On: 05/01/2020 5:47:42 AM
Post# of 155136
Great find! - what is RANTES ?
This list is the best summation, and I have read almost all of them.
--CytoDyn scientists believe their studies show that powerful immune modulator RANTES drives the pathogenic process of COVID-19.
--RANTES is chemoactive chemokine, expressed by many hematopoietic and non-hematopoietic cell types, that plays key role in controlling homing and migration of effector and memory T-cells during acute infections.
--RANTES receptor (CCR5) is co-receptor for HIV and a major target of anti-HIV drugs based on blocking viral entry.
--RANTES levels are highly elevated in COVID-19 patients and RANTES fundamentally drives the COVID-19 pathogenic process via binding of RANTES to CCR5.
--CytoDyn’s drug, a humanized monoclonal antibody called leronlimab, blocks CCR5, denying binding access to RANTES.
--Levels of RANTES return to normal very quickly after single sub-cutaneous injection of leronlimab
--Disease-associated high levels of interleukin-6, and of other chemokines, are quickly reduced to normal.
--Lung function is restored.
--Plasma viral load is reduced.
--Drug delivered by one subcutaneous injection.
http://www.bioquicknews.com/node/5307
This list is the best summation, and I have read almost all of them.
--CytoDyn scientists believe their studies show that powerful immune modulator RANTES drives the pathogenic process of COVID-19.
--RANTES is chemoactive chemokine, expressed by many hematopoietic and non-hematopoietic cell types, that plays key role in controlling homing and migration of effector and memory T-cells during acute infections.
--RANTES receptor (CCR5) is co-receptor for HIV and a major target of anti-HIV drugs based on blocking viral entry.
--RANTES levels are highly elevated in COVID-19 patients and RANTES fundamentally drives the COVID-19 pathogenic process via binding of RANTES to CCR5.
--CytoDyn’s drug, a humanized monoclonal antibody called leronlimab, blocks CCR5, denying binding access to RANTES.
--Levels of RANTES return to normal very quickly after single sub-cutaneous injection of leronlimab
--Disease-associated high levels of interleukin-6, and of other chemokines, are quickly reduced to normal.
--Lung function is restored.
--Plasma viral load is reduced.
--Drug delivered by one subcutaneous injection.
http://www.bioquicknews.com/node/5307
(4)
(0)
